跳至主要内容
临床试验/ACTRN12616001701415
ACTRN12616001701415已完成未知

Comparing the effect of Nasal High Flow (NHF) therapy with Non-invasive ventilation (NIV) on PaCO2 in COPD patients with chronic respiratory failure

Medical Research Institute of New Zealand0 个研究点目标入组 24 人开始时间: 2016年12月12日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
40 Years 至 o limit(—)
性别
All

入选标准

  • 1.A doctor’s diagnosis of COPD
  • 2. PcapCO2 >45mmHg on Capillary blood gas, at point of randomisation
  • 3.Age greater than or equal to 40 years old.

排除标准

  • 1.Smoking pack year history <10 years
  • 2.FEV1/FVC greater than or equal to 70%
  • 3.Body mass index >35
  • 4.Hypercapnea believed to be primarily due to Obesity Hypoventilation syndrome and/or Obstructive Sleep Apnoea
  • 5.Any condition which makes NIV contra-indicated as per BTS guidelines.
  • 6.Requiring greater than or equal to 4 L/min through standard nasal cannulae during the wash-in period to maintain oxygen saturations 88-92%.
  • 7.COPD not deemed to be ‘stable’:
  • a.Current exacerbation requiring acute treatment with a short course of antibiotics/oral steroids within the last 2 weeks.
  • b.Hospital admission for an acute exacerbation of COPD in the last 6 weeks.
  • 8.Nasal conditions such as deviated septum, chronic rhinitis, current cold/flu which, in the evaluation by the investigator, could impair nasal breathing.
  • 9.Any other condition, which at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or study results.

研究者

相似试验